Tmunity: Manufacturing momentum for CAR and TCR therapies

How Tmunity’s focus on CMC for its engineered T cell therapies factored into its $75M series B

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors.

Andreessen Horowitz (a16z) led the financing, which saw participation from existing investor Westlake Village BioPartners.

Westlake’s Beth Seidenberg told BioCentury that Tmunity Therapeutics Inc.’s progress over the past 18 months, including the launch of its third clinical program and its commitment to developing its own manufacturing capabilities, convinced the firm to reinvest. Tmunity Therapeutics Inc. was

Read the full 851 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers